As Deals Shrink, Indian Companies Ask MNCs To Stay Open For Drug Discovery Partnerships - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Consolidation among Big Pharma has resulted in fewer opportunities for smaller companies to out-license newly researched compounds, while the inclination of large companies to selectively work only on "first-to-market" drugs has complicated deal-making for companies with early-stage leads
You may also be interested in...
Advinus Moves Ahead With Anti-Diabetes Lead As Tata Group Looks For Strategic Allies
The Indian venture is exploring financing options even as its lead molecule shows promise.
Asia Spotlight Preview: BCG Study Of India R&D Suggests Leveraging Of "Niche Busters” And Stem Cells
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Asia Spotlight Preview: BCG Study Of India R&D Suggests Leveraging Of "Niche Busters” And Stem Cells
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.